Stock Details
ALPMF is Astellas Pharma Inc.'s stock. Stock exchange Other OTC (Currency USD). Average price in 50 days is 15.54$. Average daily volumn in 3 months 2.4k. Market cap 28.73B



Stock symbol : ALPMF. Exchange : Other OTC. Currency : USD
Lastest price : 15.55$. Total volume : 2.90k. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Astellas Pharma Inc. (ALPMF)
Last Price
15.55$
Change
0.00
Volume
2.90k

Previous Close15.55
Open15.52
Day Range15.55-15.55
Bid0.00 x N/A
Ask0.00 x N/A
Volume2.9k
Average Volume2.4k
Market Cap28.73B
Beta0.64
52 Week Range14.61-18.00
Trailing P/E29.68
Foward P/EN/A
Dividend (Yield %)3.05%
Ex-Dividend Date2022-09-29



Financial Details


According to Astellas Pharma Inc.'s financial reports the company's revenue in 2022 were 1.3T an increase(0%) over the years 2021 revenue that were of 1.25T. In 2022 the company's total earnings were 124.09B while total earnings in 2021 were 120.59B( +3.33%).


Loading ...



Organization

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatme... nt of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Market Cap:
28.73B
Revenue:
1.3T
Total Assets:
2.33T
Total Cash:
315.99B


News about "Astellas Pharma Inc."

Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Source from : Defense World - 20 hours ago

Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Rating) was the recipient of a significant decrease in short interest during the month of May. As of May 15th, there was short interest totalling 22,400 ...See details»


Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Significant Increase in Short Interest

Source from : ETF Daily News - 13 days ago

Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Rating Astellas Pharma stock opened at $15.15 on Friday. The firm has a market cap of $27.81 billion, a PE ratio of 23.00, a P/E/G ratio of 0.58 and a ...See details»


BRIEF— Astellas gets unfavorable District Court decision in Lexiscan patent dispute

Source from : The Pharma Letter - 2 days ago

Japanese drug major Astellas Pharma has confirmed the US District Court for the District of Delaware ruling that all asserted claims of the 8,106,183; 8, 524,883; and RE47301 patents for Lexiscan ...See details»


Astellas Pharma Inc. ADR

Source from : Wall Street Journal - 13 days ago

1 Day ALPMY 0.97% DJIA 1.47% S&P 500 2.39% Health Care/Life Sciences -0.20% Yoshihiko Hatanaka Chairman Sony Group Corp., Astellas Pharma, Inc. Kenji Yasukawa President, CEO & Representative ...See details»


Astellas Pharma Inc ADR - Stock Financials ALPMY

Source from : Morningstar%2c Inc. - 4 days ago

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.See details»


Astellas Pharma (OTCMKTS:ALPMY) Rating Lowered to Hold at Zacks Investment Research

Source from : ETF Daily News - 17 days ago

According to Zacks, “Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf ...See details»


Astellas Pharma Canada, Inc. Recognized as one of Canada's Best Workplaces™ for the Seventh Consecutive Year

Source from : Yahoo Finance - 29 days ago

2022 /CNW/ - Astellas Pharma Canada, Inc. has been named again on the list of Best Workplaces™ in Canada by the Great Place to Work ® Institute, marking the seventh year in a row to receive ...See details»


Market cap of Pfizer Inc. [PFE] reaches 282.73B – now what?

Source from : dbtnews - 10 days ago

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) will share new research during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 ...See details»


Astellas Pharma Canada, Inc. Welcomes Investments in Life Sciences Outlined in Ontario's 2022 Spring Budget

Source from : Yahoo - 27 days ago

MARKHAM, ON, April 29, 2022 /CNW/ - Astellas Pharma Canada, Inc., headquartered in Markham, Ontario a leader in innovative medicines, recognizes the Ontario government for the commitment of $15 ...See details»


amphastar-receives-fda-approval-for-regadenoson-image

Amphastar Receives FDA Approval for Regadenoson

Source from : Digital Journal - 2 days ago

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 24, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ...See details»


BRIEF—Astellas raises curtain on ASCO 2022 data

Source from : The Pharma Letter - 13 days ago

Japan’s Astellas Pharma has provided a preview of the research it intends to present during the 2022 American Society of Clinical Oncology (ASCO) annual meeting in early June. A total of 11 abstracts ...See details»


People with bladder cancer feel disadvantaged by their cancer, according to new report1

Source from : PharmiWeb - 6 days ago

‘Facing Bladder Cancer’ report, backed by patient group experts, highlights the true impact of the disease on mental health and emotional wellbeing felt by patients and caregivers- ADDLESTONE, UK – 19 ...See details»


Cancer Vaccines Market by Competitive Landscape and Demand 2022 – CSL Limited, Pfizer Inc., Bristol-Myers Squibb, Astrazeneca Plc.

Source from : Digital Journal - 1 days ago

Merck & Co., Inc., Astellas Pharma Inc. Currently, cancer is the second leading cause of illness and death worldwide. The major cause of cancer is gene mutation and rarely due to inherited genes.See details»


royalty-pharma-nasdaqrprx-upgraded-at-zacks-investment-research-image

Royalty Pharma (NASDAQ:RPRX) Upgraded at Zacks Investment Research

Source from : Defense World - 16 hours ago

Royalty Pharma (NASDAQ:RPRX – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports.See details»